PortalPublikationenExpression of Small Noncoding RNAs in Urinary Exosomes Class...

Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease

Standard

Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. / Wang, Wei-Lin Winnie; Sorokin, Igor; Aleksic, Ilija; Fisher, Hugh; Kaufman, Ronald P; Winer, Andrew; McNeill, Brian; Gupta, Raavi; Tilki, Derya; Fleshner, Neil; Klotz, Laurence; DiRienzo, A Gregory; Tenniswood, Martin.

in: J UROLOGY, Jahrgang 204, Nr. 3, 09.2020, S. 466-475.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wang, W-LW, Sorokin, I, Aleksic, I, Fisher, H, Kaufman, RP, Winer, A, McNeill, B, Gupta, R, Tilki, D, Fleshner, N, Klotz, L, DiRienzo, AG & Tenniswood, M 2020, 'Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease', J UROLOGY, Jg. 204, Nr. 3, S. 466-475. https://doi.org/10.1097/JU.0000000000001020

APA

Wang, W-L. W., Sorokin, I., Aleksic, I., Fisher, H., Kaufman, R. P., Winer, A., McNeill, B., Gupta, R., Tilki, D., Fleshner, N., Klotz, L., DiRienzo, A. G., & Tenniswood, M. (2020). Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. J UROLOGY, 204(3), 466-475. https://doi.org/10.1097/JU.0000000000001020

Vancouver

Wang W-LW, Sorokin I, Aleksic I, Fisher H, Kaufman RP, Winer A et al. Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. J UROLOGY. 2020 Sep;204(3):466-475. https://doi.org/10.1097/JU.0000000000001020

Bibtex

@article{35de1f58267b4945af4a12fa50056562,
title = "Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease",
abstract = "PURPOSE: This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes. The Sentinel{\texttrademark} PCa Test classifies patients with prostate cancer from subjects with no evidence of prostate cancer, the miR Sentinel CS Test stratifies patients with prostate cancer between those with low risk prostate cancer (Grade Group 1) from those with intermediate and high risk disease (Grade Group 2-5), and the miR Sentinel HG Test stratifies patients with prostate cancer between those with low and favorable intermediate risk prostate cancer (Grade Group 1 or 2) and those with high risk (Grade Group 3-5) disease.MATERIALS AND METHODS: sncRNAs were extracted from urinary exosomes of 235 participants and interrogated on miR 4.0 microarrays. Using proprietary selection and classification algorithms, informative sncRNAs were selected to customize an interrogation OpenArray{\texttrademark} platform that forms the basis of the tests. The tests were validated using a case-control sample of 1,436 subjects.RESULTS: The performance of the miR Sentinel PCa Test demonstrated a sensitivity of 94% and specificity of 92%. The Sentinel CS Test demonstrated a sensitivity of 93% and specificity of 90% for prediction of the presence of Grade Group 2 or greater cancer, and the Sentinel HG Test demonstrated a sensitivity of 94% and specificity of 96% for the prediction of the presence of Grade Group 3 or greater cancer.CONCLUSIONS: The Sentinel PCa, CS and HG Tests demonstrated high levels of sensitivity and specificity, highlighting the utility of interrogation of urinary exosomal sncRNAs for noninvasively diagnosing and classifying prostate cancer with high precision.",
keywords = "Adult, Aged, Aged, 80 and over, Algorithms, Biomarkers, Tumor/metabolism, Case-Control Studies, Exosomes/metabolism, Humans, Male, Middle Aged, Prostatic Neoplasms/metabolism, RNA, Small Untranslated/metabolism, Sensitivity and Specificity",
author = "Wang, {Wei-Lin Winnie} and Igor Sorokin and Ilija Aleksic and Hugh Fisher and Kaufman, {Ronald P} and Andrew Winer and Brian McNeill and Raavi Gupta and Derya Tilki and Neil Fleshner and Laurence Klotz and DiRienzo, {A Gregory} and Martin Tenniswood",
year = "2020",
month = sep,
doi = "10.1097/JU.0000000000001020",
language = "English",
volume = "204",
pages = "466--475",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease

AU - Wang, Wei-Lin Winnie

AU - Sorokin, Igor

AU - Aleksic, Ilija

AU - Fisher, Hugh

AU - Kaufman, Ronald P

AU - Winer, Andrew

AU - McNeill, Brian

AU - Gupta, Raavi

AU - Tilki, Derya

AU - Fleshner, Neil

AU - Klotz, Laurence

AU - DiRienzo, A Gregory

AU - Tenniswood, Martin

PY - 2020/9

Y1 - 2020/9

N2 - PURPOSE: This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes. The Sentinel™ PCa Test classifies patients with prostate cancer from subjects with no evidence of prostate cancer, the miR Sentinel CS Test stratifies patients with prostate cancer between those with low risk prostate cancer (Grade Group 1) from those with intermediate and high risk disease (Grade Group 2-5), and the miR Sentinel HG Test stratifies patients with prostate cancer between those with low and favorable intermediate risk prostate cancer (Grade Group 1 or 2) and those with high risk (Grade Group 3-5) disease.MATERIALS AND METHODS: sncRNAs were extracted from urinary exosomes of 235 participants and interrogated on miR 4.0 microarrays. Using proprietary selection and classification algorithms, informative sncRNAs were selected to customize an interrogation OpenArray™ platform that forms the basis of the tests. The tests were validated using a case-control sample of 1,436 subjects.RESULTS: The performance of the miR Sentinel PCa Test demonstrated a sensitivity of 94% and specificity of 92%. The Sentinel CS Test demonstrated a sensitivity of 93% and specificity of 90% for prediction of the presence of Grade Group 2 or greater cancer, and the Sentinel HG Test demonstrated a sensitivity of 94% and specificity of 96% for the prediction of the presence of Grade Group 3 or greater cancer.CONCLUSIONS: The Sentinel PCa, CS and HG Tests demonstrated high levels of sensitivity and specificity, highlighting the utility of interrogation of urinary exosomal sncRNAs for noninvasively diagnosing and classifying prostate cancer with high precision.

AB - PURPOSE: This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes. The Sentinel™ PCa Test classifies patients with prostate cancer from subjects with no evidence of prostate cancer, the miR Sentinel CS Test stratifies patients with prostate cancer between those with low risk prostate cancer (Grade Group 1) from those with intermediate and high risk disease (Grade Group 2-5), and the miR Sentinel HG Test stratifies patients with prostate cancer between those with low and favorable intermediate risk prostate cancer (Grade Group 1 or 2) and those with high risk (Grade Group 3-5) disease.MATERIALS AND METHODS: sncRNAs were extracted from urinary exosomes of 235 participants and interrogated on miR 4.0 microarrays. Using proprietary selection and classification algorithms, informative sncRNAs were selected to customize an interrogation OpenArray™ platform that forms the basis of the tests. The tests were validated using a case-control sample of 1,436 subjects.RESULTS: The performance of the miR Sentinel PCa Test demonstrated a sensitivity of 94% and specificity of 92%. The Sentinel CS Test demonstrated a sensitivity of 93% and specificity of 90% for prediction of the presence of Grade Group 2 or greater cancer, and the Sentinel HG Test demonstrated a sensitivity of 94% and specificity of 96% for the prediction of the presence of Grade Group 3 or greater cancer.CONCLUSIONS: The Sentinel PCa, CS and HG Tests demonstrated high levels of sensitivity and specificity, highlighting the utility of interrogation of urinary exosomal sncRNAs for noninvasively diagnosing and classifying prostate cancer with high precision.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Algorithms

KW - Biomarkers, Tumor/metabolism

KW - Case-Control Studies

KW - Exosomes/metabolism

KW - Humans

KW - Male

KW - Middle Aged

KW - Prostatic Neoplasms/metabolism

KW - RNA, Small Untranslated/metabolism

KW - Sensitivity and Specificity

U2 - 10.1097/JU.0000000000001020

DO - 10.1097/JU.0000000000001020

M3 - SCORING: Journal article

C2 - 32191585

VL - 204

SP - 466

EP - 475

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 3

ER -